연혁 1 페이지
ABOUT ATEMs
TECHNOLOGY
PIPELINE
GMP
PEOPLE
NEWS ROOM
Cartilage defect disease Global No.1 ATEMs
Cartilage defect disease Global No.1 ATEMs
Selected as the Ministry of SMEs and Startups. project
Selected as the regenerative medical technology development’ government project
Selected as the 2021 excellent venture company (by Venture Business Association)
Changed to be managed by the two CEO system- Park Sang-hyug and Min Byoung-hyun
GMP production: Regenerative therapy product (Seoul), Medical device(Deajeon) secured
Relocation of Head Office(Munjeong-dong, Songpa-gu, Seoul)
Selected as a project by Ministry of Healthy and Welfares
Series A investment from HansbioMed Co., Ltd.
Selected as a project by TIPS / Korea Institute of Marine Science & Technology
Promotion / Ministry of Health and Welfare
Certified as Venture Company(Korean Venture Capital Association)
Completion of transfer of 6 key patents/ 14 exclusive license contracts.
Joint technology development agreement with Brilliant Research Pte. Ltd.
Establishment of a corporate-affiliated research institute.
Foundation of ATEMs Co., Ltd. in Kwanggyo, Suwon
4 patents granted in Korea and Japan (in 2015-2021)
IND submission for A-paste-C phase 1/2 clinical trial
Completion of non-clinical trial of incurable disease treatments based on
source cells and source materials
Development of cell therapy product-based technology
/ Approval of ArtiCell (cell therapy product) product
First autologous chondrocyte implantation procedure in Korea
(the second ACI procedure in the world)
Ajou University Medical Center, Cell Therapy Center
Selected as the Ministry of SMEs and Startups. project
Selected as the regenerative medical technology development’
government project
Selected as the 2021 excellent venture company
(by Venture Business Association)
Changed to be managed by the two CEO system-
Park Sang-hyug and Min Byoung-hyun
GMP production: Regenerative therapy product (Seoul),
Medical device(Deajeon) secured
Relocation of Head Office(Munjeong-dong, Songpa-gu, Seoul)
Selected as a project by Ministry of Healthy and Welfares
Series A investment from HansbioMed Co., Ltd.
Selected as a project by TIPS / Korea Institute of Marine Science
& Technology Promotion / Ministry of Health and Welfare Certified
as Venture Company (Korean Venture Capital Association)
Completion of transfer of 6 key patents/ 14 exclusive license contracts.
Joint technology development agreement with Brilliant Research
Pte. Ltd. Establishment of a corporate-affiliated research institute.
Foundation of ATEMs Co., Ltd. in Kwanggyo, Suwon
4 patents granted in Korea and Japan (in 2015-2021)
IND submission for A-paste-C phase 1/2 clinical trial
Completion of non-clinical trial of incurable disease treatments
based on source cells and source materials
Development of cell therapy product-based technology
/ Approval of ArtiCell (cell therapy product) product
First autologous chondrocyte implantation procedure in Korea
(the second ACI procedure in the world)
Ajou University Medical Center, Cell Therapy Center
Headquarters / Seoul Research Institute : 7th and 9th floors, Jeongui-ro 8-gil, Songpa-gu, Seoul (Hans Building)
Ceo : Park Sanghyuk / Min ByunghyunBusiness Licence : 160-86-00908Tel : 02-401-7943 E-mail : info@atems.co.kr
Copyright ⓒ 2021 ATEMs. All Rights Reserved.
Copyright ⓒ 2021 ATEMs. All Rights Reserved.
Headquarters / Seoul Research Institute :
7th and 9th floors, Jeongui-ro 8-gil, Songpa-gu, Seoul (Hans Building)
Ceo : Park Sanghyuk / Min ByunghyunBusiness Licence : 160-86-00908
Tel : 02-401-7943E-mail : info@atems.co.kr
Copyright ⓒ 2021 ATEMs. All Rights Reserved.
Ko
Ko
